Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

JARDIANCE Drug Profile

« Back to Dashboard

Which patents cover Jardiance, and what substitute generic drugs are available?

Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and thirty-four patent family members in thirty-six countries.

The generic ingredient in JARDIANCE is empagliflozin. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.

Summary for Tradename: JARDIANCE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list30
Clinical Trials: see list14
Patent Applications: see list67
Drug Prices:see details
DailyMed Link:JARDIANCE at DailyMed

Pharmacology for Tradename: JARDIANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo8,551,957► Subscribe ► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-002Aug 1, 2014RXYesYes► Subscribe► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: JARDIANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,687,469Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JARDIANCE

Country Document Number Estimated Expiration
Israel218714► Subscribe
Uruguay29505► Subscribe
Austria557013► Subscribe
Colombia6251239► Subscribe
Germany602006011310► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: JARDIANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0074France► SubscribePRODUCT NAME: EMPAGLIFLOZINE ET SES SELS, EN PARTICULIER L'EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930 20140522
00696Netherlands► SubscribePRODUCT NAME: EMPAGLIFLOZINE EN ZOUTEN DAARVAN, IN HET BIJZONDER EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930/001-009 20140522
0 5026-2014Slovakia► SubscribePRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/14/930 20140527
0140033 00134Estonia► SubscribePRODUCT NAME: EMPAGLIFLOSIIN;REG NO/DATE: EU/1/14/930 27.05.2014
14/055Ireland► SubscribePRODUCT NAME: EMPAGLIFLOZIN AND SALTS THEREOF, IN PARTICULAR EMPAGLIFLOZIN ((1S)-1,5- ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXOLAN-3-YL)OXY))PHENYL)METHYL)PHENYL)- D-GLUCITOL); REGISTRATION NO/DATE: EU/1/14/930 20140522
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc